Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002

  • Authors:
    • Sergio Diotaiuti
    • Simona De Summa
    • Rosanna  Altieri
    • Caterina  Dantona
    • Stefania  Tommasi
    • Maria  Di Gennaro
    • Giuseppe  Rubini
    • Maria   Irene Pastena
    • Antonella  Argentiero
    • Francesco   Alfredo Zito
    • Nicola  Silvestris
    • Angelo   Virgilio Paradiso
  • View Affiliations

  • Published online on: July 1, 2020     https://doi.org/10.3892/ol.2020.11793
  • Pages: 2469-2476
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The current study examined if cancer biomarker phenotyping could predict the clinical/pathological status of axillary nodes in women with primary breast cancer. Primary breast cancers from 2002 were analyzed for tumor size, estrogen receptor (ER), progesterone receptor (PgR), Ki‑67MIB expression and Her2/neu amplification. Relationships between the clinical and pathological status of the axilla and the biological subtypes classification were analyzed using univariate, multivariate and regression tree analysis. A total of 65% of women with axillary nodes clinically involved had complete axillary node dissection (ALND) while 705 women with clinically negative axillary underwent sentinel lymph node biopsy (SLNB), 18.5% of the latter had at least one pathologically SLNB involved node. Multivariate analysis revealed that the Luminal A subtype was significantly associated (OR 0.62; P<10‑9) with clinical negative axilla while HER2pos/not Luminal was associated with clinical positivity (OR 1.71; P<0.01). No significant association between biological subtypes and SLNB status was demonstrated. Regression tree analysis revealed that subgroups with significantly different probability of SLNB status were separated according to tumor size and PgR values. In conclusion, the current study demonstrated that biomarker breast cancer phenotyping is significantly associated with clinical status of axillary nodes but not with pathological involvement of nodes at SLNB. Regression tree analysis could represent a valid attempt to individualize some patients subgroups candidate to different surgical axilla approaches.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Diotaiuti S, De Summa S, Altieri R, Dantona C, Tommasi S, Di Gennaro M, Rubini G, Pastena MI, Argentiero A, Zito FA, Zito FA, et al: Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. Oncol Lett 20: 2469-2476, 2020
APA
Diotaiuti, S., De Summa, S., Altieri, R., Dantona, C., Tommasi, S., Di Gennaro, M. ... Paradiso, A.V. (2020). Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. Oncology Letters, 20, 2469-2476. https://doi.org/10.3892/ol.2020.11793
MLA
Diotaiuti, S., De Summa, S., Altieri, R., Dantona, C., Tommasi, S., Di Gennaro, M., Rubini, G., Pastena, M. I., Argentiero, A., Zito, F. A., Silvestris, N., Paradiso, A. V."Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002". Oncology Letters 20.3 (2020): 2469-2476.
Chicago
Diotaiuti, S., De Summa, S., Altieri, R., Dantona, C., Tommasi, S., Di Gennaro, M., Rubini, G., Pastena, M. I., Argentiero, A., Zito, F. A., Silvestris, N., Paradiso, A. V."Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002". Oncology Letters 20, no. 3 (2020): 2469-2476. https://doi.org/10.3892/ol.2020.11793